BioMed Research International / 2017 / Article / Tab 2

Research Article

Systems Study on the Antirheumatic Mechanism of Tibetan Medicated-Bath Therapy Using Wuwei-Ganlu-Yaoyu-Keli

Table 2

Genes encoding drug targets for FDA approved anti-RA drugs that appear in the network modules.

ModuleDrug targetDrugDrug class

()JAK1TofacitinibDMARDs
JAK2TofacitinibDMARDs

()IL1BCanakinumabBiotech agents
IL6RTocilizumabBiotech agents
LTAEtanerceptBiotech agents
TNFEtanerceptBiotech agents
AdalimumabBiotech agents
InfliximabBiotech agents
GolimumabBiotech agents
Certolizumab pegolBiotech agents
ChloroquineDMARDs
TNFRSF1BEtanerceptBiotech agents

()IL1R1AnakinraBiotech agents

()PTK2BLeflunomideDMARDs

()MAPK3SulindacNSAIAs

()CHUKSulfasalazineDMARDs
IKBKBSulfasalazineDMARDs
AuranofinDMARDs

()PDPK1CelecoxibNSAIAs

()BCL2IbuprofenNSAIAs

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.